Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Cervical cancer; Early breast cancer; Gallbladder cancer; Gastric cancer; Lung cancer; Nasopharyngeal cancer; Oesophageal cancer; Ovarian cancer; Salivary gland cancer; Sarcoma; Soft tissue sarcoma; Squamous cell cancer
- Focus Therapeutic Use
- 14 Feb 2018 Status changed from recruiting to completed.
- 28 Jan 2018 Planned End Date changed from 30 Jun 2018 to 28 Jan 2018.
- 03 Jan 2018 New trial record